Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGenus PLC

Genus PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2340.0 GBX 18.00 ( 0.78%)
Last update at 2026-10-27T16:38:00Z
VOLUME
144162
Market Cap
1701.51M
P/E
36.08

Momentum Score

…

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2304.00
Low
2354.00
High
52 Week Price Range
1538.00
Low
3206.84
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Genus plc develops and sells elite genetics plus reproductive and genomic services for cattle and pigs globally through its ABS (bovine) and PIC (porcine) operations. Long-term growth may be supported by rising protein demand, wider adoption of genomic selection and reproductive technologies, and efficiency gains, while it is positioned to benefit from recurring product sales and an R&D-led competitive moat.
Key investment risks include sensitivity to farm-level commodity price cycles that can reduce demand, biological and disease outbreaks, regulatory or animal-welfare restrictions, and competition from other breeders and biotech firms.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2322.00
Dividend Yield
1.25%
Revenue TTM
672.00M
Revenue Per Share
10.18
Gross Profit TTM
269.60M
Debt / Equity
0.56
ROE
9.35%
Net Debt
217.90M
ROCE
6.38%
Diluted EPS TTM
0.71

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 28.50M 5.50M 39.40M 48.40M 55.80M
Minority interest 0.00M 5.50M 1.50M 4.20M -1.50M
Net income 19.30M 7.90M 33.30M 40.90M 47.30M
Selling general administrative - 109.10M 93.10M 85.50M 88.70M
Selling and marketing expenses - 101.80M - - -
Gross profit 672.80M 178.70M 239.30M 215.20M 216.80M
Reconciled depreciation 44.70M 46.90M 43.60M 39.00M 35.10M
Ebit 49.00M 26.80M 51.00M 49.40M 47.70M
Ebitda 93.70M 73.70M 94.60M 93.10M 95.40M
Depreciation and amortization 44.70M 46.90M 43.60M 43.70M 47.70M
Operating income 42.40M 6.40M 40.50M 49.40M 47.70M
Other operating expenses 630.40M 662.40M 649.20M 542.40M 523.30M
Interest expense 20.50M 21.70M 14.30M 5.70M 4.50M
Tax provision - 3.10M 7.60M 11.70M 9.00M
Interest income 2.60M 3.90M 1.10M 0.40M 0.40M
Net interest income - -18.30M -14.30M -6.20M -5.00M
Income tax expense 9.20M 3.10M 16.60M 11.70M 9.00M
Total revenue 672.80M 668.80M 689.70M 593.40M 574.30M
Total operating expenses 630.40M 172.30M -649.20M 164.20M 165.80M
Cost of revenue - 490.10M 450.40M 378.20M 357.50M
Total other income expense net -13.90M -0.90M -1.10M -1.00M 8.10M
Net income from continuing ops 28.50M 2.40M 39.40M 48.40M 55.80M
Net income applicable to common shares - - 33.30M 40.90M 47.30M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 899.00M 1028.90M 1007.50M 1017.90M 851.00M
Intangible assets 55.30M 65.40M 66.20M 72.00M 56.30M
Other current assets 16.20M 16.70M 1.50M 134.70M 109.10M
Total liab 423.00M 485.00M 440.30M 445.80M 354.40M
Total stockholder equity 475.60M 548.20M 569.40M 572.80M 493.00M
Other current liab 78.60M 77.10M 98.20M 98.10M 1.60M
Common stock 6.60M 6.60M 6.60M 6.60M 6.60M
Capital stock 6.60M 6.60M 6.60M 6.60M 6.60M
Retained earnings 321.60M 351.20M 360.60M 340.60M 320.40M
Other liab - - 75.20M 87.90M 83.20M
Good will 102.80M 110.30M 107.80M 111.00M 101.50M
Other assets - - 347.80M 354.60M 289.70M
Cash 48.00M 42.50M 36.30M 38.80M 46.00M
Total current liabilities 131.30M 150.60M 147.20M 151.30M 142.50M
Current deferred revenue - 8.10M - - 7.70M
Net debt 217.90M 248.70M 195.80M 185.00M 105.60M
Short term debt 16.20M 18.90M 14.20M 17.20M 22.90M
Short long term debt 2.90M 4.90M 4.20M 7.10M 13.90M
Short long term debt total 265.90M 291.20M 232.10M 223.80M 151.60M
Other stockholder equity 179.00M 179.00M 202.20M 225.60M 166.00M
Property plant equipment - - 164.40M 171.40M 123.00M
Total current assets 254.40M 271.10M 259.00M 257.50M 231.70M
Net tangible assets - - 400.90M 395.50M 340.30M
Net receivables 109.30M 122.50M 91.50M 101.00M 102.20M
Long term debt 215.90M 228.20M 196.00M 182.10M 109.40M
Inventory 80.90M 89.40M 85.10M 84.00M 76.60M
Accounts payable 25.30M 34.00M 34.80M 36.00M 110.30M
Accumulated other comprehensive income -31.10M 11.40M - - -
Common stock total equity - - - - 6.60M
Treasury stock - - - - -0.10M
Non currrent assets other 219.00M 310.40M 393.60M 395.90M 330.50M
Non current assets total 644.60M 757.80M 748.50M 760.40M 619.30M
Capital lease obligations 47.10M 58.10M 31.90M 34.60M 28.30M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -13.80M -19.30M -30.90M -67.20M -3.30M
Change to liabilities - - 6.60M 2.20M 17.90M
Total cashflows from investing activities -13.80M -19.30M -30.90M -67.20M -46.70M
Net borrowings -5.40M 31.90M 4.00M 43.50M 7.30M
Total cash from financing activities -46.60M -2.80M -18.20M 21.90M -14.20M
Net income 19.30M 7.90M 31.80M 36.70M 46.80M
Change in cash 5.50M 6.20M -2.50M -7.20M 4.70M
Begin period cash flow 42.50M 36.30M 38.80M 46.00M 41.30M
End period cash flow 48.00M 42.50M 36.30M 38.80M 46.00M
Total cash from operating activities 67.20M 29.80M 50.40M 34.30M 67.50M
Issuance of capital stock - - 0.00M 0.00M 0.10M
Depreciation 44.70M 47.00M 43.60M 39.00M 35.10M
Other cashflows from investing activities 1.30M -6.70M 0.70M 3.20M 3.70M
Dividends paid 21.10M 21.00M 21.00M 20.90M 19.50M
Change to inventory 2.00M -1.30M -9.60M -6.10M -1.30M
Change to account receivables 11.40M -10.10M -9.30M -18.50M -11.00M
Sale purchase of stock - - - - 0.10M
Other cashflows from financing activities -20.10M -13.70M 114.50M 126.70M 181.30M
Change to netincome - - -15.30M -24.10M -21.40M
Capital expenditures 18.60M 24.70M 35.20M 50.90M 33.80M
Change in working capital 11.30M -11.20M -12.30M -22.40M 5.60M
Stock based compensation 6.90M 7.00M 6.00M 3.70M 7.70M
Other non cash items -15.00M -20.90M 21.10M -22.70M 5.00M
Free cash flow 48.60M 5.10M 15.20M -16.60M 33.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04
IBT
International Biotechnology Trust plc		 5.00
0.49%		 1020.00 - 714.29 16.40 1.20 15.60 -

Profile*

Genus PLC

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Matrix House, Basingstoke, United Kingdom, RG21 4FF

44 1256 347 100

https://www.genusplc.com

3190

Name Title Year Born
Mr. Stephen Wilson CEO & Exec. Director 1960
Ms. Alison Henriksen CFO & Exec. Director 1967
Dr. William Christianson Chief Operating Officer NA
Dr. Elena Rice Head of R&D and Chief Scientific Officer NA
Mr. Dan Hartley Group Gen. Counsel & Company Sec. NA
Ms. Angelle R. Rosata Group HR Director NA
Mr. Jerry Thompson Chief Operating Officer of Genus ABS Beef NA
Dr. Nate Zwald Chief Operating Officer of Genus ABS Dairy NA
Ms. Janet Duane Group Financial Controller NA
Mr. Jorgen Kokke Chief Executive Officer & Executive Director 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…